Akums Drugs & Pharmaceuticals Ltd. Share Price Target from 2025 to 2050: Future Outlook
Akums Drugs & Pharmaceuticals Ltd. is a leading contract pharmaceutical manufacturer in India, providing development, manufacturing, and packaging services to global and domestic pharma players. With a wide range of dosage capabilities and proximity to regulatory clients, Akums is poised to benefit from the outsourcing trends in the pharmaceutical supply chain. In this post, we analyze Akums’ Share Price Target & Forecast from 2025 to 2050, exploring its operations, investment strengths, associated risks, and future growth drivers.
Akums Drugs & Pharmaceuticals Ltd. Overview: Growth, Products, & Market Presence
| Information | Details |
|---|---|
| Founded | 1994 (Derabassi, Punjab, India) |
| Sector | Pharmaceutical Contract Manufacturing |
| Key Segments | Oral solids, clinical trial manufacturing, sterile injectables, packaging |
| Stock Listings | NSE: AKUMS, BSE: 543452 |
| Market Reach | Supplies to Indian and international pharma companies, particularly in regulated markets |
Akums serves as a vital manufacturing partner, offering end-to-end pharma solutions backed by WHO-GMP compliant facilities. Its strong relationships with global pharma players position it as a trusted outsourcing destination for regulated markets.
On this page, you will find detailed insights into Akums Drugs & Pharmaceuticals Ltd.’s stock, including real-time prices, technical analysis, and long-term forecasts:
✅ Real-Time Stock Price: Updated every minute with the latest market data.
✅ Technical Indicators: Tailored by time frame for accurate trading insights.
✅ Financial Reports: Published quarterly to reflect the company’s performance.
✅ Stock Charts: Refreshed in real time for visual market analysis.
📊 Note: Akums Drugs & Pharmaceuticals Ltd.’s stock forecast prices in the tables are automatically updated based on live asset price changes.
Akums Drugs & Pharmaceuticals Ltd. Financial Overview & Key Metrics
Akums generates revenue through long-term contracts, which support stable cash flows and capacity utilization rates. Profitability generally hinges on contract volumes and operational tariffs.
Below is a detailed breakdown of its key financial figures, including revenue, net profit, earnings per share (EPS), and other crucial metrics. These insights enable investors to assess the company’s financial health and long-term growth potential.
Use the landscape mode for best viewing on mobile devices.
Investment Potential & Associated Risks
Why Consider Investing in Akums Drugs & Pharmaceuticals Ltd.?
- Leader in CDMO services: Akums is one of India’s premier names in contract development and manufacturing (CDMO), capturing a growing shift of western companies towards cost-efficient Indian partners.
- Regulatory compliance edge: Multiple WHO-GMP, ISO certifications, and proximity to US/EU clients position Akums strongly in global pharma supply chains.
- Capacity for injectables and high-value products: With multiple sterile filling lines and trial manufacturing capabilities, Akums can command higher pricing and improved margins.
- Repeat business model: Long-term, volume-backed contracts drive high plant utilization and predictable revenue streams over time.
- Strong overseas client base: Export revenue from regulated markets gives Akums superior pricing power and protectiveness from domestic competition.
Risks to Consider
- Pricing pressure from global clients: As competition grows, clients may demand lower rates or faster turnarounds, compressing margins.
- Regulatory audit risk: Any adverse finding in FDA/EU inspections could trigger delays or suspensions, hurting contracts and reputation.
- Reliance on large clients: High dependency on a few key contracts can pose earnings risks if one doesn’t renew or shifts volumes elsewhere.
- Operational scale and expansion risks: Growth via facility expansion or new dosage forms carries project execution risks and requires calibration with client demand.
- Currency volatility exposure: A large part of revenue comes from exports; fluctuations in USD/INR rates can impact margins and earnings.
Akums Drugs & Pharmaceuticals Share Price Target: Tomorrow & Weekly Outlook
Akums Drugs & Pharmaceuticals stock price forecasts for tomorrow and the upcoming week are based on recent market trends, historical price movements, and key technical indicators. These projections provide valuable insights into potential price changes, enabling traders and investors to make informed decisions.
However, various factors can influence stock prices, including market sentiment, news updates, and global events; therefore, it’s always wise to stay updated and flexible with your strategies.
📊 Below, you will find the expected stock price targets for the coming days:
| Date | Min. Price | Max. Price | Stock Price |
|---|---|---|---|
| 19-Sep | 461.56 | 472.87 | 467.38 |
| 22-Sep | 464.58 | 475.84 | 470.17 |
| 23-Sep | 465.91 | 476.94 | 471.19 |
| 24-Sep | 465.68 | 477.19 | 471.50 |
| 25-Sep | 460.65 | 472.04 | 466.69 |
| 26-Sep | 458.60 | 469.71 | 464.40 |
| 29-Sep | 461.55 | 472.64 | 467.20 |
| 30-Sep | 462.19 | 474.38 | 468.22 |
| 01-Oct | 462.79 | 474.05 | 468.53 |
Technical Analysis of Akums Drugs & Pharmaceuticals Ltd. Using Key Indicators
For Akums Drugs & Pharmaceuticals Ltd., you can leverage indicator-based technical analysis to identify optimal market entry and exit points. Adjust the time frame according to your trading strategy for more accurate insights.
How to Interpret Technical Analysis Signals:
How to Interpret Technical Analysis Signals:
| ✅ Sell” or “Strong Sell | Indicates bearish (negative) market sentiment, suggesting a potential decline. |
| ✅ Buy” or “Strong Buy | Indicates bullish (positive) market sentiment, signaling a potential uptrend. |
Time Frame Considerations:
- Short-Term Analysis (Intraday/Short Swing Trading): Use time frames ranging from 15 minutes to 2 hours.
- Medium to Long-Term Analysis: If you plan to hold for more than a week, use daily to weekly time frames.
Below, you will find technical indicator-based buy and sell signals based on different time frames to assist in your investment decisions.
Future Growth Drivers for Akums Drugs & Pharmaceuticals Ltd.
- Expansion of CDMO ordering: As pharma companies trend toward outsourcing globally, Akums stands to benefit from both volume increases and higher-value contract wins.
- Injectables and high-margin formulations: Scaling sterile and oncological manufacturing can boost gross margins relative to commodity oral solids.
- Regulated market diversification: Beyond US/EU, entering new pharmaceutical markets like Japan or Australia could broaden the client and pricing base.
- Backward integration opportunities: Sourcing APIs or excipients in-house may reduce costs and improve supply control.
- Biopharma and specialty dosage forms: Venturing into biosimilars, drug-device combinations, or inhalation medicines can unlock premium pricing and deeper partnerships.
What Will Drive Akums Drugs & Pharmaceuticals’ Share Price Over the Coming Decades?
- Scaling CDMO contracts
- Shift toward injectables and complex manufacturing
- Client wins in new regulatory markets
- Increased upstream integration
- Diversified high-margin specialty products
Akums Drugs & Pharmaceuticals Share Price Target & Forecast (2025-2050)
This long-term stock price forecast for Akums Drugs & Pharmaceuticals Ltd. is based on historical market trends, the company’s growth prospects, and industry analysis. While forecasting stock prices for the long term involves uncertainty, these forecasts help investors gain insight into potential future price movements.
📊 The following table presents the Akums Drugs & Pharmaceuticals share price target forecast from 2025 to 2050, based on current market trends and available data.
| Year | Min. Price | Max. Price |
|---|---|---|
| 2025 | ₹ 453.04 | ₹ 477.98 |
| 2026 | ₹ 376.76 | ₹ 457.95 |
| 2027 | ₹ 300.47 | ₹ 381.66 |
| 2028 | ₹ 224.18 | ₹ 305.37 |
| 2029 | ₹ 147.89 | ₹ 229.09 |
| 2030 | ₹ 93.61 | ₹ 152.28 |
| 2031 | ₹ 24.04 | ₹ 41.53 |
| 2032 | ₹ 0.00 | ₹ 0.00 |
| 2033 | ₹ 0.00 | ₹ 0.00 |
| 2034 | ₹ 0.00 | ₹ 0.00 |
| 2035 | ₹ 0.00 | ₹ 0.00 |
| 2040 | ₹ 0.00 | ₹ 0.00 |
| 2050 | ₹ 0.00 | ₹ 0.00 |
The Akums Drugs And Pharmaceutical Ltd. share price targets provided here are for informational purposes only. Both short-term and long-term stock price predictions are based on historical data and market trends, but actual prices may vary due to market fluctuations and external factors. This forecast assumes positive market conditions and does not account for unforeseen risks, economic uncertainties, or company-specific challenges. Investors should conduct their research before making any financial decisions.
Akums Drugs And Pharmaceutical Share Price Target Year-wise Breakdown (2025 to 2050)
Akums Drugs And Pharmaceutical Share Price Target 2025
oops, no data
Akums Drugs And Pharmaceutical Share Price Target 2026
oops, no data
Akums Drugs And Pharmaceutical Share Price Target 2027
oops, no data
Akums Drugs And Pharmaceutical Share Price Target 2028
oops, no data
Akums Drugs And Pharmaceutical Share Price Target 2029
oops, no data
Akums Drugs And Pharmaceutical Share Price Target 2030
oops, no data
Akums Drugs And Pharmaceutical Share Price Target 2040
oops, no data
Akums Drugs And Pharmaceutical Share Price Target 2050
oops, no data
Live Stock Chart & Price Trends – Akums Drugs & Pharmaceuticals Ltd.
Track Akums Drugs And Pharmaceutical Ltd.’s stock performance in real time with our interactive chart below. This live tool provides up-to-the-minute price movements, trading volume, and market trends, helping investors and market watchers stay fully informed. Easily switch between intraday, daily, weekly, or monthly views, and apply a variety of technical indicators to support deeper analysis. Whether you’re actively trading or simply monitoring the market, this chart offers the insights you need to make smart, timely decisions.
🔗 Also Read: Divi’s Laboratories Share Price Target: Future Outlook
Divi’s Laboratories Ltd. is a globally recognized Indian pharmaceutical company known for manufacturing active pharmaceutical ingredients (APIs), intermediates, and custom synthesis of drug compounds. Read more
Expert Opinions & Market Sentiment
Brokerage & Analyst Ratings
HDFC Securities: Positive – Contract outsourcing demand and new facility capacity create structural tailwinds.
Axis Securities: Accumulate – Strong compliance track record and pipeline of new long-term contracts support medium-term earnings visibility.
Investor Sentiment & Market Trends
Institutional investors appreciate Akums for its high client quality and plant compliance credentials. Retail interest is building around its CDMO potential and structured growth, though concerns remain on margin sustainability amid pricing pressure.
❓FAQs
Is Akums a good long‑term investment?
Yes—if you believe in the rising trend of global pharma outsourcing and the company’s ability to win recurring contracts in regulated markets.
What are Akums’ growth drivers?
Growth is driven by expansion in CDMO ordering, sterile injectables, regulatory approvals, and client diversification.
Does Akums pay dividends?
Yes—dividend payouts are modest and aligned with its free cash flow and capital allocation discipline.
How does it compare with other CDMOs?
Its compliance focus and capacity for injectables position it uniquely among Indian CDMOs, offering depth beyond generic API players.
What should investors monitor?
Key factors include contract wins, inspection outcomes, utilization growth, pricing trends, and currency fluctuations.
Price Prediction Methodology
Our predictions combine expert analysis, technical indicators, and algorithmic models to provide an informed outlook.
📊 Want to know more? Click here to read our full methodology.
